Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Phase 3 data expected in the second half of 2024
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Marks the World Head & Neck Cancer Day at the OCTF Conference
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Subscribe To Our Newsletter & Stay Updated
